ADVM
Adverum Biotechnologies Inc.
$3.40
-$0.36(-9.57%)
10
Overall
--
Value
10
Tech
--
Quality
Market Cap
$78.90M
Volume
806.84K
52W Range
$1.78 - $8.56
Target Price
$19.50
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $2.3M | $1.5M | $1.8M | $1.6M | $250.0K | -- | $7.5M | -- | $3.6M | $1.0M | ||
| Total Revenue | $2.3M | $1.5M | $1.8M | $1.6M | $250.0K | -- | $7.5M | -- | $3.6M | $1.0M | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | $-100.0K | $-600.0K | $-500.0K | $-100.0K | -- | -- | -- | -- | -- | -- | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $2.3M | $1.5M | $1.8M | $1.6M | $250.0K | -- | $7.5M | -- | $3.6M | $1.0M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $-50.1M | $-116.7M | $-60.7M | $-79.7M | $-68.8M | $118.0M | $153.6M | $157.1M | $132.5M | $140.2M | ||
| Research & Development | $25.5M | $31.7M | $39.8M | $50.1M | $40.4M | $73.3M | $89.2M | $99.3M | $77.5M | $77.0M | ||
| Research Expense | $25.5M | $31.7M | $39.8M | $50.1M | $40.4M | $73.3M | $89.2M | $99.3M | $77.5M | $77.0M | ||
| Selling, General & Administrative | $22.1M | $24.4M | $20.9M | $24.6M | $28.4M | $44.6M | $64.4M | $57.9M | $55.1M | $63.1M | ||
| General & Administrative Expenses | $22.1M | $24.4M | $20.9M | $24.6M | $28.4M | $44.6M | $64.4M | $57.9M | $55.1M | $63.1M | ||
| Salaries & Wages | $-11.5M | $-11.4M | $-8.7M | $-13.4M | $-9.9M | $300.0K | $1.6M | -- | -- | -- | ||
| Depreciation & Amortization | $-812.0K | $-1.6M | $-2.1M | $-1.8M | $-1.6M | $4.2M | -- | -- | -- | -- | ||
| Depreciation & Amortization | $-812.0K | $-1.6M | $-2.1M | $-1.8M | $-1.6M | $4.2M | -- | -- | -- | -- | ||
| Other Operating Expenses | $-50.1M | $-116.7M | $-60.7M | $-4.1M | $-995.0K | $-5.1M | $-2.6M | $-2.5M | -- | -- | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-45.3M | $-54.6M | $-58.8M | $-73.1M | $-68.5M | $-118.0M | $-146.1M | $-157.1M | $-128.9M | $-139.2M | ||
| EBITDA | $-45.9M | $-112.9M | $-53.5M | $-72.1M | $-64.2M | $-113.8M | $-141.5M | $-150.6M | $-99.3M | $-119.8M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Intinc | -- | -- | -- | $4.2M | $4.1M | -- | -- | -- | -- | -- | ||
| Net Non-Operating Interest Income/Expense | -- | -- | -- | $4.2M | $4.1M | -- | -- | -- | -- | -- | ||
| Gain on Sale of Securities | $-6.0K | $6.0K | $-182.0K | $168.0K | $33.0K | -- | -- | -- | -- | -- | ||
| Other Income/Expense | $-364.0K | $-768.0K | $-2.5M | $-168.0K | $-33.0K | $-1.6M | $-154.0K | $2.7M | $-6.8M | $-8.3M | ||
| Other Special Charges | $370.0K | $762.0K | $2.7M | $4.2M | -- | $1.6M | $582.0K | $2.7M | $5.7M | $8.2M | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | $2.6M | -- | -- | -- | -- | -- | -- | $4.7M | -- | -- | ||
| Special Income Charges | $-2.6M | $-60.7M | -- | $-5.0M | -- | -- | $-1.1M | $-6.8M | $-224.0K | -- | ||
| Impairment of Capital Assets | -- | $60.7M | -- | $5.0M | -- | -- | $1.1M | $2.1M | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-47.5M | $-114.5M | $-56.1M | $-73.9M | $-64.5M | $-118.0M | $-146.1M | $-157.1M | $-123.2M | $-130.9M | ||
| Pre-Tax Income | $-47.5M | $-114.5M | $-56.1M | $-73.9M | $-64.5M | $-116.4M | $-145.5M | $-154.5M | $-123.2M | $-130.9M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | -- | $-775.0K | $-10.2M | $-1.3M | $-298.0K | $1.1M | $-7.0K | $74.0K | $-1.1M | -- | ||
| NET INCOME | ||||||||||||
| Net Income | $-47.5M | $-113.7M | $-56.3M | $-72.5M | $-64.5M | $-117.5M | $-145.5M | $-154.5M | $-122.1M | $-130.9M | ||
| Net Income (Continuing Operations) | $-47.5M | $-113.7M | $-56.3M | $-72.5M | $-64.5M | $-117.5M | $-145.5M | $-154.5M | $-122.1M | $-130.9M | ||
| Net Income (Discontinued Operations) | $-47.5M | $-113.7M | $-56.3M | $-72.5M | $-64.5M | $-117.5M | $-145.5M | $-154.5M | $-122.1M | $-130.9M | ||
| Net Income (Common Stockholders) | $-47.5M | $-113.7M | $-56.3M | $-72.5M | $-64.5M | $-117.5M | $-145.5M | $-154.5M | $-122.1M | $-130.9M | ||
| TOTALS | ||||||||||||
| Total Expenses | $-50.2M | $-117.3M | $-61.2M | $79.7M | $-68.8M | $118.0M | $153.6M | $157.1M | $132.5M | $140.2M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $25.5M | $36.2M | $43.7M | $61.4M | $64.1M | $85.1M | $98.0M | $9.9M | $10.1M | $19.8M | ||
| Average Shares Outstanding (Diluted) | $25.5M | $36.2M | $43.7M | $61.4M | $63.8M | $85.1M | $98.0M | $9.9M | $10.1M | $19.8M | ||
| Shares Outstanding | $26.9M | $42.1M | $62.2M | $63.2M | $79.7M | $9.8M | $9.9M | $10.1M | $20.8M | $20.9M | ||
| Basic EPS | -- | -- | -- | -- | -- | $-1.38 | $-1.48 | $-15.6 | $-11.6 | $-6.62 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | -- | $-1.38 | $-1.48 | $-15.6 | $-11.6 | $-6.62 | ||
| Diluted EPS | $-1.86 | $-3.14 | $-1.29 | $-1.18 | $-1.01 | $-1.38 | $-1.48 | $-15.6 | $-11.6 | $-6.62 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | -- | $-1.48 | $-15.6 | $-11.6 | $-6.62 | ||
| OTHER METRICS | ||||||||||||
| Other Gand A | $22.1M | $24.4M | $20.9M | $24.6M | $28.4M | $44.6M | $64.4M | $57.9M | $55.1M | $63.1M | ||
| Other Impairment Of Capital Assets | -- | $-11.2M | -- | -- | -- | -- | $800.0K | -- | -- | -- | ||
| Rent And Landing Fees | $22.1M | $24.4M | $20.9M | $24.6M | $28.4M | -- | -- | -- | -- | -- | ||
| Restruct | $2.6M | -- | -- | -- | -- | -- | -- | $4.7M | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ADVM | $3.40 | -9.6% | 806.84K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Adverum Biotechnologies Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW